Kara Penne

1.1k citations
11 papers · 691 indexed · 1 hit paper · h-index 7

Kara Penne

11 papers receiving 671 citations

Hit Papers

Phase II Trial of Gefitinib in Recurrent Glioblastoma5582003202620102018100200300400500

Peers

Kara Penne
Comparison fields: 5 of 64
  • Genetics 375
  • Cancer Research 154
  • Oncology 256
  • Pulmonary and Respiratory Medicine 203
  • Pathology and Forensic Medicine 88
Replace L. Pronk with:
L. Pronk Netherlands
Gil Awada Belgium
Matteo Clavarezza Italy
T Fujimoto Japan
Abhijit Ramachandran United States
Francesca Benevento Italy
Bertil Uggla Sweden
Alicja Gruszka Italy
Gilad W. Vainer Israel
Yuri Kamitsuji Japan
Kara Penne relative to L. Pronk Netherlands L. Pronk's profile →
Citations per field
00.5×
L. Pronk · 1×
Citations per year

Countries citing papers authored by Kara Penne

Since Specialization
Citations

This map shows the geographic impact of Kara Penne's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kara Penne with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kara Penne more than expected).

Fields of papers citing papers by Kara Penne

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kara Penne. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kara Penne. The network helps show where Kara Penne may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Kara Penne, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Kara Penne Line = papers co-authored together Kara Penne links everyone, so they are left out of the graph.

All Works

11 of 11 papers shown
#Work
1 20153
2 201412
3 201443
4 201421
5 200611
6 200530
7
Results of a phase II trial with iodine 131-labeled murine antitenascin monoclonal antibody 81C6 (m81C6) via surgically created resection cavities in the treatment of patients with recurrent malignant brain tumors
20041
8 20042
9
Phase II Trial of Gefitinib in Recurrent Glioblastomabreakdown →
2003558
10 20031
11 20029

About Kara Penne

Kara Penne is a scholar working on Emergency Medical Services, Oncology and Critical Care and Intensive Care Medicine, having authored 11 papers that have together received 691 indexed citations. Recurring topics across this work include Pancreatic and Hepatic Oncology Research (4 papers), Esophageal and GI Pathology (3 papers), Clinical practice guidelines implementation (2 papers), Central Venous Catheters and Hemodialysis (2 papers), Glioma Diagnosis and Treatment (2 papers), Colorectal Cancer Treatments and Studies (2 papers), Urinary Tract Infections Management (1 paper) and RNA modifications and cancer (1 paper). The work is most often cited by research in Genetics (375 citations), Cancer Research (154 citations) and Oncology (256 citations). Kara Penne has collaborated with scholars based in United States and France. Frequent co-authors include James E. Herndon, Jennifer A. Quinn, James J. Vredenburgh, Henry S. Friedman, Jeremy N. Rich, David A. Reardon, Darell D. Bigner, Allan H. Friedman, Jeannette M. Dowell and Carol J. Wikstrand. Their work appears in journals such as Journal of Clinical Oncology, Neuro-Oncology and Journal of Surgical Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026